SCHEMBL733007

SCHEMBL733007

c1ccc([C](c2ccccc2)c2ccncc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.65
MEN1 O00255 1/20 0.65
ALDH1A1 P00352 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP3A4 P08684 2/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C9 P11712 2/20 0.58
HPGD P15428 2/20 0.58
CYP2C19 P33261 2/20 0.58
PLOD2 O00469 1/20 0.58
PLOD3 O60568 1/20 0.58
PLOD1 Q02809 1/20 0.58
HIF1A Q16665 1/20 0.58
NAPRT Q6XQN6 1/20 0.52
CYP19A1 P11511 1/20 0.52
CYP11B2 P19099 1/20 0.52
NOTUM Q6P988 1/20 0.50
HTT P42858 1/20 0.48
JAK2 O60674 1/20 0.48
TYK2 P29597 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18983076 0.83 KMT2A (0.65) KMT2AMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL25983244 0.83 KMT2A (0.65) KMT2AMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL143 0.82 CES1 (0.53) KMT2AMEN1ALDH1A1CYP3A4HPGD
SCHEMBL3271740 0.79 KMT2A (0.60) KMT2AMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL3074392 0.79 KMT2A (0.74) KMT2AMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL17115264 0.79 KMT2A (0.60) KMT2AMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL229650 0.79 KMT2A (1.00) KMT2AMEN1ALDH1A1CYP1A2CYP3A4
SCHEMBL6246649 0.79 KMT2A (0.60) KMT2AMEN1ALDH1A1CYP1A2CYP3A4
Bromide SCHEMBL28972076 0.78 CES1 (0.50) KMT2AMEN1ALDH1A1CYP3A4HPGD
SCHEMBL28839155 0.78 CES1 (0.50) KMT2AMEN1ALDH1A1CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024110477-A2 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-05-30 WO claimed
WO-2024042448-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB GRANULES INDIA LIMITED (IN) 2024-02-29 WO claimed
EP-3985008-A1 PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR Incyte Holdings Corporation (US) 2022-04-20 EP claimed
CN-111875607-B Preparation method of chiral pyrrolopyrimidine compound 正大天晴药业集团股份有限公司 2021-12-03 CN claimed
US-20210253584-A1 Processes for Preparing Jak Inhibitors and Related Intermediate Compounds INCYTE HOLDINGS CORPORATION 2021-08-19 US claimed
EP-3398952-B1 SYNTHESIS PROCESS OF RUXOLITINIB CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-07-14 EP claimed
EP-3473625-B1 PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-06-02 EP claimed
CN-111875607-A Preparation method of chiral pyrrolopyrimidine compound 正大天晴药业集团股份有限公司 2020-11-03 CN claimed
US-10766901-B2 Preparation method for chiral pyrrolopyrimidine compound CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-09-08 US claimed
CN-109311892-B Preparation method of chiral pyrrolopyrimidine compound 正大天晴药业集团股份有限公司 2020-09-04 CN claimed
EP-0983237-A1 CHEMICAL PROCESS FOR THE REDUCTION OF 1-SUBSTITUTED -3-HYDROXYMETHYL-4- (4-FLUOROPHENYL)TETRAHYDROPYRIDINES KNOLL AKTIENGESELLSCHAFT (DE) 2000-03-08 EP claimed
WO-1998052920-A1 CHEMICAL PROCESS FOR THE REDUCTION OF 1-SUBSTITUTED -3-HYDROXYMETHYL-4- (4-FLUOROPHENYL)TETRAHYDROPYRIDINES KNOLL AKTIENGESELLSCHAFT (DE) 1998-11-26 WO claimed
EP-0474789-B1 CYSTEINE THIOL-PROTECTED PEPTIDES FOR USE IN IMMUNOASSAYS GENETIC SYSTEMS CORP (US) 1998-01-28 EP claimed
EP-0788487-A1 PROCESS FOR THE PREPARATION OF TETRAZOLES Novartis AG (CH) 1997-08-13 EP claimed
WO-1996013489-A1 PROCESS FOR THE PREPARATION OF TETRAZOLES NOVARTIS AG (CH) 1996-05-09 WO claimed
US-5439792-A Synthesizing a cyclic viral protein epitope GENETIC SYSTEMS CORPORATION (US) 1995-08-08 US claimed
US-5360928-A Synthesis and use of amino acid fluorides as peptide coupling reagents RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1994-11-01 US claimed
EP-0474789-A4 CYSTEINE THIOL-PROTECTED PEPTIDES FOR USE IN IMMUNOASSAYS 1992-06-03 EP claimed
EP-0474789-A1 CYSTEINE THIOL-PROTECTED PEPTIDES FOR USE IN IMMUNOASSAYS GENETIC SYSTEMS CORPORATION (US) 1992-03-18 EP claimed
WO-1990015071-A1 CYSTEINE THIOL-PROTECTED PEPTIDES FOR USE IN IMMUNOASSAYS GENETIC SYSTEMS CORPORATION (US) 1990-12-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253584-A1 Processes for Preparing Jak Inhibitors and Related Intermediate Compounds JAK3, JAK1, JAK2 KMT2A 1913/4885MEN1 3188/4885ALDH1A1 3122/4885
US-10766901-B2 Preparation method for chiral pyrrolopyrimidine compound DHPS, DPYD, MPHOSPH6 KMT2A 2265/4885MEN1 2666/4885ALDH1A1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.